These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 34755131)

  • 1. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
    Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
    Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
    Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
    Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
    Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
    Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
    Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
    Topalian SL; Bhatia S; Amin A; Kudchadkar RR; Sharfman WH; Lebbé C; Delord JP; Dunn LA; Shinohara MM; Kulikauskas R; Chung CH; Martens UM; Ferris RL; Stein JE; Engle EL; Devriese LA; Lao CD; Gu J; Li B; Chen T; Barrows A; Horvath A; Taube JM; Nghiem P
    J Clin Oncol; 2020 Aug; 38(22):2476-2487. PubMed ID: 32324435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.
    Wondergem NE; Miedema IHC; van de Ven R; Zwezerijnen GJC; de Graaf P; Karagozoglu KH; Hendrickx JJ; Eerenstein SEJ; Bun RJ; Mulder DC; Voortman J; Boellaard R; Windhorst AD; Hagers JP; Peferoen LAN; de Gruijl TD; Bloemena E; Brakenhoff RH; Leemans CR; Menke-van der Houven van Oordt CW
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39038919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma.
    Xiong Y; Neskey DM; Horton JD; Paulos CM; Knochelmann HM; Armeson KE; Young MRI
    BMC Cancer; 2020 Mar; 20(1):229. PubMed ID: 32183719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
    Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM
    Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
    Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
    J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
    Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
    N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
    Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
    Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
    Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
    PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.
    Trafalis DT; Alifieris CE; Kalantzis A; Verigos KE; Vergadis C; Sauvage S
    J Immunother; 2018; 41(6):300-305. PubMed ID: 29642086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.